Syra Health Achieves First Profitable Quarter in Q1 2026 with Strong Revenue Growth and Margin Expansion
Summary
Syra Health Corp. reported its first profitable quarter in Q1 2026, with a net income of $241,000, a 22% increase in revenue, and expanded gross margins.
Key Events
-
Achieved First Profitable Quarter
Syra Health Corp. reported a net income of $240,979 for Q1 2026, a significant improvement from a net loss of $(472,265) in Q1 2025, marking its first profitable quarter.
-
Strong Revenue Growth
Total revenue increased by 22% year-over-year to $2.3 million in Q1 2026, driven by a 46% growth in population health solutions.
-
Expanded Gross Margin
Gross margin rose by 11 percentage points to 42.7% in Q1 2026, up from 31.7% in the prior year period, reflecting a shift towards higher-margin solutions and improved operating leverage.
-
Positive EPS and EBITDA
Diluted EPS grew to $0.02 per share compared to ($0.04) in Q1 2025, and Adjusted EBITDA improved materially to $244,495 from a loss of $(462,239) in the prior year.
Analysis
This 8-K filing announces a significant milestone for Syra Health Corp., marking its first-ever profitable quarter. For a company with a market capitalization of approximately $5.37 million, achieving a net income of $241,000 represents a substantial turnaround and a strong validation of its business model. The 22% year-over-year revenue growth, coupled with an 11 percentage point expansion in gross margin, indicates robust operational improvements and effective cost management. The increase in cash on hand to $2.9 million, with no long-term debt, significantly strengthens the company's financial position and provides a solid runway for future operations. This positive financial performance, especially for a micro-cap company, is a critical signal of improved financial health and potential for sustainable growth.
At the time of this filing, SYRA was trading at $0.45 on OTC in the Trade & Services sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $0.03 to $0.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.